-$0.53 Earnings Per Share Expected for Mersana Therapeutics, Inc. (NASDAQ:MRSN) This Quarter

Wall Street brokerages expect that Mersana Therapeutics, Inc. (NASDAQ:MRSNGet Rating) will report ($0.53) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Mersana Therapeutics’ earnings, with estimates ranging from ($0.60) to ($0.48). Mersana Therapeutics posted earnings of ($0.59) per share in the same quarter last year, which would indicate a positive year over year growth rate of 10.2%. The business is scheduled to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Mersana Therapeutics will report full year earnings of ($2.13) per share for the current year, with EPS estimates ranging from ($2.51) to ($1.98). For the next financial year, analysts expect that the firm will post earnings of ($2.07) per share, with EPS estimates ranging from ($2.62) to ($1.75). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Mersana Therapeutics.

Mersana Therapeutics (NASDAQ:MRSNGet Rating) last posted its earnings results on Monday, May 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.28). Mersana Therapeutics had a negative net margin of 8,826.73% and a negative return on equity of 119.10%. During the same quarter last year, the firm earned ($0.50) earnings per share.

A number of analysts have recently weighed in on MRSN shares. SVB Leerink reduced their price objective on shares of Mersana Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, February 18th. Zacks Investment Research cut shares of Mersana Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. Robert W. Baird reduced their price objective on shares of Mersana Therapeutics from $23.00 to $18.00 in a research note on Tuesday, May 10th. Finally, HC Wainwright reduced their price objective on shares of Mersana Therapeutics from $24.00 to $19.00 in a research note on Monday, May 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $17.80.

Shares of Mersana Therapeutics stock traded down $0.11 on Friday, reaching $3.15. The stock had a trading volume of 53,977 shares, compared to its average volume of 1,724,128. The business’s 50-day moving average price is $3.87 and its two-hundred day moving average price is $5.10. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.28 and a current ratio of 4.28. Mersana Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $15.34. The stock has a market cap of $305.52 million, a P/E ratio of -1.31 and a beta of 2.37.

In other Mersana Therapeutics news, Director Andrew A. F. Hack purchased 135,292 shares of the stock in a transaction on Monday, May 16th. The shares were purchased at an average price of $3.10 per share, with a total value of $419,405.20. Following the acquisition, the director now directly owns 7,872,692 shares of the company’s stock, valued at approximately $24,405,345.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Andrew A. F. Hack purchased 15,599 shares of the stock in a transaction on Monday, May 23rd. The stock was acquired at an average cost of $3.35 per share, for a total transaction of $52,256.65. Following the acquisition, the director now directly owns 8,302,999 shares in the company, valued at $27,815,046.65. The disclosure for this purchase can be found here. Insiders have purchased 1,060,245 shares of company stock worth $4,025,409 in the last ninety days. 5.30% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. bought a new stake in Mersana Therapeutics during the 1st quarter worth approximately $36,000. Quantbot Technologies LP acquired a new stake in shares of Mersana Therapeutics in the 1st quarter valued at approximately $37,000. Virtu Financial LLC acquired a new stake in shares of Mersana Therapeutics in the 1st quarter valued at approximately $53,000. Ensign Peak Advisors Inc acquired a new stake in shares of Mersana Therapeutics in the 4th quarter valued at approximately $56,000. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of Mersana Therapeutics in the 4th quarter valued at approximately $57,000. Institutional investors own 92.74% of the company’s stock.

About Mersana Therapeutics (Get Rating)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.

Featured Articles

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.